Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alexandria Real Estate Equities Inc (ARE) vs Revvity Inc (RVTY) Price & Performance

Alexandria Real Estate Equities IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Alexandria Real Estate Equities Inc vs Revvity Inc — how do they compare? Alexandria Real Estate Equities Inc trades at $48.32 (market cap $8.28B), while Revvity Inc trades at $116.99 (market cap $12.91B). The key difference: Revvity Inc is the larger of the two by market cap, and Alexandria Real Estate Equities Inc pays the higher dividend (5.99%). Which is the better fit depends on your goals.

ARERVTY
Market Cap
$8.28B$12.91B
Sector
Real EstateTechnology
52-Week High
$87.45$117.75
52-Week Low
$40.41$82.26
Enterprise Value
$20.98B$15.23B
Dividend Yield
5.99%0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alexandria Real Estate Equities Inc

Alexandria Real Estate Equities (ARE) trades at $48.01, down 0.7% on the day, with a bearish technical signal and mixed fundamentals. The stock shows negative profitability with a net income margin of -37.12% and ROE of -6.29% for 2025, though it maintains a strong gross margin of 67.28%. Recent Q2 2026 earnings missed EPS expectations but beat on FFO, with leasing momentum improving. The current price is near the analyst low target of $48.00, with support at $47 and resistance at $49.

Outlook remains cautious due to persistent net losses and high debt, but a 36% analyst buy rating and recent institutional acquisitions suggest potential recovery if leasing trends and FFO guidance hold. Key risks include occupancy pressures, legal scrutiny, and macroeconomic sensitivity. The stock presents a speculative opportunity for value investors betting on a real estate turnaround.

Revvity Inc

RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.

The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.

Returns comparison

Trailing returns across standard periods

About Alexandria Real Estate Equities Inc

Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.

Read more on ARE

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY